1. Emergence of Small-Molecule Non-RGD-Mimetic Inhibitors for RGD Integrins
   Lisa M. Miller et al, 2017, J. Med. Chem. CrossRef
2. Integrin Activation Contributes to Lower Cisplatin Sensitivity in MV3 Melanoma Cells by Inducing the Wnt Signalling Pathway
   Maria Piva et al, 2017, Cancers CrossRef
3. Effects of WD-3 on tumor growth and the expression of integrin αvβ3 and ERK1/2 in mice bearing human gastric cancer using the 18F-RGD PET/CT imaging system
   Chunhui Jin et al, 2017 CrossRef
4. The Effect of Stromal Integrin β3-Deficiency on Two Different Tumors in Mice
   Inga Reigstad et al, 2016, Cancers CrossRef
5. An αv-RGD Integrin Inhibitor Toolbox: Drug Discovery Insight, Challenges and Opportunities
   Richard J. D. Hatley et al, 2018, Angew. Chem. Int. Ed. CrossRef
6. Ein Instrumentarium von αv-RGD-Integrin-Inhibitoren: Wirkstoffsuche, Herausforderungen und Möglichkeiten
   Richard J. D. Hatley et al, 2018, Angew. Chem. CrossRef
7. Integrins as therapeutic targets in the organ-specific metastasis of human malignant melanoma
   Ruixia Huang et al, 2018, J Exp Clin Cancer Res CrossRef
8. Biological Effects Induced by 68Ga-Conjugated Peptides in Human and Rodent Tumor Cell Lines
   Marieta Elena Panait et al, 2018, Int J Pept Res Ther CrossRef
9. Overcoming the Limitations of γ, and δ-C–H Arylation of Amines through Ligand Development
   Yan-Qiao Chen et al, 2018, J. Am. Chem. Soc. CrossRef
10. Tetrac Delayed the Onset of Ocular Melanoma in an Orthotopic Mouse Model
    Osnat Ashur-Fabian et al, 2019, Front. Endocrinol. CrossRef
11. The functional role of integrins during intra- and extravasation within the metastatic cascade.
    Greta Sökeland et al, 2019, Mol Cancer CrossRef
12. Limiting tumor seeding as a therapeutic approach for metastatic disease
    Asurayya Worrede-Mahdi et al, 2019, Pharmacology & Therapeutics CrossRef
13. Roles of integrin in tumor development and the target inhibitors
    Zhao-He LI et al, 2019, Chinese Journal of Natural Medicines CrossRef
14. Novel Pure αVβ3 Integrin Antagonists That Do Not Induce Receptor Extension, Prime the Receptor, or Enhance Angiogenesis at Low Concentrations
    Jihong Li et al, 2019, ACS Pharmacol. Transl. Sci. CrossRef
15. Melanoma progression.
    David E Elder, 2016, Pathology CrossRef
16. Patent highlights August–September 2016
    Hermann AM Mucke, 2017, Pharmaceutical Patent Analyst CrossRef
17. null
    Zhenqiang Yao et al, 2019 CrossRef
18. Integrins as A New Target for Cancer Treatment
    Izabela Łasiñska et al, 2019, ACAMC CrossRef
19. null
    Rafael Luís et al, 2020 CrossRef
20. A Penicillin Derivative Exerts an Anti-Metastatic Activity in Melanoma Cells Through the Downregulation of Integrin αvβ3 and Wnt/β-Catenin Pathway
    Elizabeth Barrionuevo et al, 2020, Front. Pharmacol. CrossRef
21. The role of integrins in melanoma: a review
    Suzette M. Arias‐Mejias et al, 2020, Int J Dermatol CrossRef
22. Small Ones to Fight a Big Problem—Intervention of Cancer Metastasis by Small Molecules
    Dennis Kobelt et al, 2020, Cancers CrossRef
23. The osteoclast cytoskeleton – current understanding and therapeutic perspectives for osteoporosis
    Anne Blangy et al, 2020, J Cell Sci CrossRef
24. Cell Adhesion Molecules in Plasticity and Metastasis.
    Jessica A Smart et al, 2021, Mol Cancer Res CrossRef
25. RGD-Binding Integrins Revisited: How Recently Discovered Functions and Novel Synthetic Ligands (Re-)Shape an Ever-Evolving Field
    Beatrice S. Ludwig et al, 2021, Cancers CrossRef
26. Comprehensive understanding of anchorage-independent survival and its implication in cancer metastasis
    Zhong Deng et al, 2021, Cell Death Dis CrossRef
27. Anti-Proliferative and Anti-Migratory Activities of Hispidulin on Human Melanoma A2058 Cells
    Chi-Jen Chang et al, 2021, Biomolecules CrossRef
28. Exosomes and organ-specific metastasis
    Lei Zhao et al, 2021, Molecular Therapy - Methods & Clinical Development CrossRef
29. Tumor metastasis: Mechanistic insights and therapeutic interventions
    Mengmeng Liu et al, 2021, MedComm CrossRef
30. Inhibition of angiogenesis and tumor progression of MK-0429, an integrin αvβ3 antagonist, on oral squamous cell carcinoma
    Takayuki Nakagawa et al, 2022, J Cancer Res Clin Oncol CrossRef
31. null
    C. B. Nanthakumar et al, 2020 CrossRef
32. The Association of Integrins β3, β4, and αVβ5 on Exosomes, CTCs and Tumor Cells with Localization of Distant Metastasis in Breast Cancer Patients
    Evgeniya S. Grigoryeva et al, 2023, IJMS CrossRef
33. The Roles of Exosomes in Metastasis of Sarcoma: From Biomarkers to Therapeutic Targets
    Linyun Tan et al, 2023, Biomolecules CrossRef
34. Therapeutic targeting of anoikis resistance in cutaneous melanoma metastasis
    Hannah M. Neuendorf et al, 2023, Front. Cell Dev. Biol. CrossRef
35. Small molecule– and peptide–drug conjugates addressing integrins: A story of targeted cancer treatment
    Jannik Paulus et al, 2024, Journal of Peptide Science CrossRef
36. Sentinel lymph node risk prognostication in primary cutaneous melanoma through tissue-based profiling, potentially redefining the need for sentinel lymph node biopsy
    Julian Kött et al, 2024, European Journal of Cancer CrossRef
37. Sidechain structure–activity relationships of cyclobutane-based small molecule αvβ3 antagonists
    Adam Throup et al, 2024, RSC Med. Chem. CrossRef
38. Core Modifications of GSK3335103 toward Orally Bioavailable αvβ6 Inhibitors with Improved Synthetic Tractability
    Heather F. Hryczanek et al, 2024, J. Med. Chem. CrossRef
39. Extracellular Matrix as a Target in Melanoma Therapy: From Hypothesis to Clinical Trials
    Yuriy P. Mayasin et al, 2024, Cells CrossRef